Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Anastrozole Cuts Breast Cancer Incidence in Half for Women at High Risk

December 13th 2013

Anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.

NeoALTTO Analysis Finds Significant Link Between pCR and Survival

December 12th 2013

Pathologic complete response to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.

No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer

December 12th 2013

Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.

Dasatinib Added to Aromatase Inhibitor Extends PFS in HER2-Negative MBC

December 12th 2013

Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled PFS compared with letrozole alone in women with HR-positive, HER2-negative metastatic breast cancer.

Dr. Arteaga Discusses the CALGB 40603 Trial

December 12th 2013

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

Select Older Patients Can Avoid Radiation After Breast-Conserving Surgery

December 12th 2013

Women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy after breast conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence.

Dr. Kent Osborne Discusses the PRIME 2 Trial

December 12th 2013

C. Kent Osborne, MD, professor of medicine and molecular and cell biology, Baylor College of Medicine, discusses the impact of the results of the PRIME 2 trial, which looked at radiotherapy after surgery in women over 65 years old with breast cancer.

Benefits of Screening Mammography Not So Inconsistent, After All

December 12th 2013

The benefit of screening mammography is more consistent across studies than has previously been thought, according to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium.

High Levels of Infiltrating Lymphocytes May Identify Better Response to Trastuzumab

December 12th 2013

New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.

Dr. Jennifer Litton on the Phase III BETH Trial

December 11th 2013

Jennifer Litton, MD, associate professor, Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, discusses the results of the BETH trial.

Dr. Loi on the Association Between TILs and Trastuzumab

December 11th 2013

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.

Mammogram Study Provides Rationale for Expanding Screening Programs

December 5th 2013

Most deaths from breast cancer occur in women who have not been regularly screened and whose tumors are diagnosed at a median age 49 years, confirming the need for the greater use of annual mammography in younger women, according to a recent study that marks the latest episode in the debate over screening guidelines.

Dr. McTiernan on Biomarkers in Breast Cancer

December 4th 2013

Anne McTiernan, MD, PhD, research professor of epidemiology, University of Washington, member, Fred Hutchinson Cancer Research Center, discusses the biomarkers that are associated with poor prognosis in patients with breast cancer.

Dr. Finn on AMG900 in Breast Cancer

December 2nd 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

Quest Diagnostics Launches New BRCA 1/2 Test

December 2nd 2013

Quest Diagnostics, a business founded 46 years ago in a medical resident's two-room apartment, has parlayed the exponential subsequent growth in medical testing into an operation worth $8.5 billion.

Immediate Impact Anticipated From Neoadjuvant Pertuzumab

November 27th 2013

The new indication for pertuzumab (Perjeta) as part of a three-drug neoadjuvant regimen for patients with HER2-positive metastatic breast cancer marks the first time the FDA has authorized a therapy based on pathologic complete response.

SABCS 2013 Preview: Breast Cancer Diagnosis and Treatment

November 26th 2013

Presentations at the 36th San Antonio Breast Cancer Symposium (SABCS) will tackle key topics and questions regarding the treatment of breast cancer.

Two Studies Suggest Pattern of Misuse for Breast MRIs

November 23rd 2013

Two large cohort studies, suggest that the costly scan is being overused in women who won't benefit from it and underused in women who could gain benefit from it.

G-CSF Prophylaxis Recommended Throughout Chemotherapy in Breast Cancer Patients at Risk for Febrile Neutropenia

November 22nd 2013

A Dutch team is recommending the continued use of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis throughout all chemotherapy cycles in women with early breast cancer who are at high risk of febrile neutropenia (FN).

Dr. Finn Discusses Research in Triple-Negative Breast Cancer

November 19th 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).